Autonomic control of pancreatic polypeptide and glucagon secretion during neuroglucopenia and hypoglycemia in mice

Peter J Havel, J. O. Akpan, D. L. Curry, J. S. Stern, R. L. Gingerich, B. Ahren

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Neural control of pancreatic polypeptide (PP) release has not been previously investigated in the mouse. In addition, it is not known to what extent increased glucagon secretion during hypoglycemia in mice is neurally mediated vs. an effect of hypoglycemia to directly stimulate glucagon secretion at the level of the islet. Feeding or the cholinergic agonist carbachol increased plasma PP levels in conscious mice (+74 ± 18 pg/ml vs. fasted mice and +141 ± 17 pg/ml vs. control, respectively). Neuroglucopenia induced by 2-deoxy-D-glucose or insulin-induced hypoglycemia also increased plasma PP (+79 ± 18 and +89 ± 11 pg/ml vs. control, respectively). These increases were abolished by hexamethonium and reduced by atropine methylnitrate (atropine). Hypoglycemia-induced hyperglucagonemia (+1,243 ± 275 pg/ml) was reduced to 31 ± 7% of control by atropine (+382 ± 85 pg/ml), to 48 ± 9% of control by combined adrenergic blockade (+601 ± 112 pg/ml), and nearly abolished by atropine plus combined blockade (+143 ± 41 pg/ml; 11 ± 3% of control) or hexamethonium (+151 ± 38 pg/ml; 12 ± 3% of control). We conclude the following in the mouse. 1) Feeding or cholinergic agonists increase plasma PP. 2) During neuroglucopenia or hypoglycemia, plasma PP is increased via nicotinic and muscarinic mechanisms. 3) The glucagon response to hypoglycemia is predominantly the result of autonomic activation and is mediated by both muscarinic and adrenergic mechanisms.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume265
Issue number1 34-1
StatePublished - 1993

Fingerprint

Pancreatic Polypeptide
Glucagon
Hypoglycemia
Atropine
Cholinergic Agonists
Hexamethonium
Adrenergic Agents
Cholinergic Agents
Deoxyglucose
Carbachol
Insulin

Keywords

  • 2-deoxy-D-glucose
  • atropine
  • carbachol
  • hexamethonium
  • insulin-induced hypoglycemia
  • parasympathetic nervous system
  • phentolamine
  • propranolol
  • sympathetic nervous system

ASJC Scopus subject areas

  • Physiology

Cite this

Autonomic control of pancreatic polypeptide and glucagon secretion during neuroglucopenia and hypoglycemia in mice. / Havel, Peter J; Akpan, J. O.; Curry, D. L.; Stern, J. S.; Gingerich, R. L.; Ahren, B.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 265, No. 1 34-1, 1993.

Research output: Contribution to journalArticle

@article{f88fe92b246e4335af0a43769c037f04,
title = "Autonomic control of pancreatic polypeptide and glucagon secretion during neuroglucopenia and hypoglycemia in mice",
abstract = "Neural control of pancreatic polypeptide (PP) release has not been previously investigated in the mouse. In addition, it is not known to what extent increased glucagon secretion during hypoglycemia in mice is neurally mediated vs. an effect of hypoglycemia to directly stimulate glucagon secretion at the level of the islet. Feeding or the cholinergic agonist carbachol increased plasma PP levels in conscious mice (+74 ± 18 pg/ml vs. fasted mice and +141 ± 17 pg/ml vs. control, respectively). Neuroglucopenia induced by 2-deoxy-D-glucose or insulin-induced hypoglycemia also increased plasma PP (+79 ± 18 and +89 ± 11 pg/ml vs. control, respectively). These increases were abolished by hexamethonium and reduced by atropine methylnitrate (atropine). Hypoglycemia-induced hyperglucagonemia (+1,243 ± 275 pg/ml) was reduced to 31 ± 7{\%} of control by atropine (+382 ± 85 pg/ml), to 48 ± 9{\%} of control by combined adrenergic blockade (+601 ± 112 pg/ml), and nearly abolished by atropine plus combined blockade (+143 ± 41 pg/ml; 11 ± 3{\%} of control) or hexamethonium (+151 ± 38 pg/ml; 12 ± 3{\%} of control). We conclude the following in the mouse. 1) Feeding or cholinergic agonists increase plasma PP. 2) During neuroglucopenia or hypoglycemia, plasma PP is increased via nicotinic and muscarinic mechanisms. 3) The glucagon response to hypoglycemia is predominantly the result of autonomic activation and is mediated by both muscarinic and adrenergic mechanisms.",
keywords = "2-deoxy-D-glucose, atropine, carbachol, hexamethonium, insulin-induced hypoglycemia, parasympathetic nervous system, phentolamine, propranolol, sympathetic nervous system",
author = "Havel, {Peter J} and Akpan, {J. O.} and Curry, {D. L.} and Stern, {J. S.} and Gingerich, {R. L.} and B. Ahren",
year = "1993",
language = "English (US)",
volume = "265",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "1 34-1",

}

TY - JOUR

T1 - Autonomic control of pancreatic polypeptide and glucagon secretion during neuroglucopenia and hypoglycemia in mice

AU - Havel, Peter J

AU - Akpan, J. O.

AU - Curry, D. L.

AU - Stern, J. S.

AU - Gingerich, R. L.

AU - Ahren, B.

PY - 1993

Y1 - 1993

N2 - Neural control of pancreatic polypeptide (PP) release has not been previously investigated in the mouse. In addition, it is not known to what extent increased glucagon secretion during hypoglycemia in mice is neurally mediated vs. an effect of hypoglycemia to directly stimulate glucagon secretion at the level of the islet. Feeding or the cholinergic agonist carbachol increased plasma PP levels in conscious mice (+74 ± 18 pg/ml vs. fasted mice and +141 ± 17 pg/ml vs. control, respectively). Neuroglucopenia induced by 2-deoxy-D-glucose or insulin-induced hypoglycemia also increased plasma PP (+79 ± 18 and +89 ± 11 pg/ml vs. control, respectively). These increases were abolished by hexamethonium and reduced by atropine methylnitrate (atropine). Hypoglycemia-induced hyperglucagonemia (+1,243 ± 275 pg/ml) was reduced to 31 ± 7% of control by atropine (+382 ± 85 pg/ml), to 48 ± 9% of control by combined adrenergic blockade (+601 ± 112 pg/ml), and nearly abolished by atropine plus combined blockade (+143 ± 41 pg/ml; 11 ± 3% of control) or hexamethonium (+151 ± 38 pg/ml; 12 ± 3% of control). We conclude the following in the mouse. 1) Feeding or cholinergic agonists increase plasma PP. 2) During neuroglucopenia or hypoglycemia, plasma PP is increased via nicotinic and muscarinic mechanisms. 3) The glucagon response to hypoglycemia is predominantly the result of autonomic activation and is mediated by both muscarinic and adrenergic mechanisms.

AB - Neural control of pancreatic polypeptide (PP) release has not been previously investigated in the mouse. In addition, it is not known to what extent increased glucagon secretion during hypoglycemia in mice is neurally mediated vs. an effect of hypoglycemia to directly stimulate glucagon secretion at the level of the islet. Feeding or the cholinergic agonist carbachol increased plasma PP levels in conscious mice (+74 ± 18 pg/ml vs. fasted mice and +141 ± 17 pg/ml vs. control, respectively). Neuroglucopenia induced by 2-deoxy-D-glucose or insulin-induced hypoglycemia also increased plasma PP (+79 ± 18 and +89 ± 11 pg/ml vs. control, respectively). These increases were abolished by hexamethonium and reduced by atropine methylnitrate (atropine). Hypoglycemia-induced hyperglucagonemia (+1,243 ± 275 pg/ml) was reduced to 31 ± 7% of control by atropine (+382 ± 85 pg/ml), to 48 ± 9% of control by combined adrenergic blockade (+601 ± 112 pg/ml), and nearly abolished by atropine plus combined blockade (+143 ± 41 pg/ml; 11 ± 3% of control) or hexamethonium (+151 ± 38 pg/ml; 12 ± 3% of control). We conclude the following in the mouse. 1) Feeding or cholinergic agonists increase plasma PP. 2) During neuroglucopenia or hypoglycemia, plasma PP is increased via nicotinic and muscarinic mechanisms. 3) The glucagon response to hypoglycemia is predominantly the result of autonomic activation and is mediated by both muscarinic and adrenergic mechanisms.

KW - 2-deoxy-D-glucose

KW - atropine

KW - carbachol

KW - hexamethonium

KW - insulin-induced hypoglycemia

KW - parasympathetic nervous system

KW - phentolamine

KW - propranolol

KW - sympathetic nervous system

UR - http://www.scopus.com/inward/record.url?scp=0027320216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027320216&partnerID=8YFLogxK

M3 - Article

C2 - 8102036

AN - SCOPUS:0027320216

VL - 265

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 1 34-1

ER -